Catalyst Pharmaceuticals’ FIRDAPSE® Launches in Japan

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a leader in developing therapies for rare diseases, announced that its sub-licensee, DyDo Pharma, Inc., has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan. The therapy is now available for improving muscle weakness in patients with Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder causing muscle weakness and fatigue.

“This launch is a testament to our commitment to health equity and expanding access to life-changing therapies worldwide,” said Richard J. Daly, Catalyst’s President and CEO. FIRDAPSE, already FDA-approved in the U.S. for adults and children aged six and older, is a key part of Catalyst’s mission to support rare disease communities globally. This milestone further solidifies the company's dedication to improving patient outcomes through international partnerships.